Progress and Prospects: Immune Responses to Viral Vectors
By Sushrusha Nayak, R. Herzog. Gene Therapy, 2009
626 citations recorded by the source corpus.
Viral vectors are potent gene delivery platforms used for the treatment of genetic and acquired diseases. However, just as viruses have evolved to infect cells efficiently, the immune system has evolved to fight off what it perceives as invading pathogens. Therefore, innate immunity and antigen-specific adaptive immune responses against vector-derived antigens reduce the efficacy and stability of in vivo gene transfer. In addition, a number of vectors are derived from parent viruses that humans encounter through natural infection, resulting in preexisting antibodies and possibly in memory responses against vector antigens. Similarly, antibody and T-cell responses may be directed against therapeutic gene products that often differ from the endogenous nonfunctional or absent protein that is being replaced. As details and mechanisms of such immune reactions are uncovered, novel strategies are being developed, and vectors are being specifically engineered to avoid, suppress or manipulate the response, ideally resulting in sustained expression and immune tolerance to the transgene product. This review provides a summary of our current knowledge of the interactions between the immune system adeno-associated virus, adenoviral and lentiviral vectors, and their transgene products.
Subfields: Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/bd4003e222eaa798e5f0866058deadae5caef21c
Citations in the corpus
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “Another limitation of using adenoviruses is the strong immunological response that they potentially induce, even though new species are being tested to reduce these effects (reviewed in Nayak & Herzog, 2010).”